Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2014 1
2015 2
2016 3
2017 3
2018 5
2019 3
2020 2
2021 4
2022 4
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.
Butler J, Anker SD, Lund LH, Coats AJS, Filippatos G, Siddiqi TJ, Friede T, Fabien V, Kosiborod M, Metra M, Piña IL, Pinto F, Rossignol P, van der Meer P, Bahit C, Belohlavek J, Böhm M, Brugts JJ, Cleland JGF, Ezekowitz J, Bayes-Genis A, Gotsman I, Goudev A, Khintibidze I, Lindenfeld J, Mentz RJ, Merkely B, Montes EC, Mullens W, Nicolau JC, Parkhomenko A, Ponikowski P, Seferovic PM, Senni M, Shlyakhto E, Cohen-Solal A, Szecsödy P, Jensen K, Dorigotti F, Weir MR, Pitt B. Butler J, et al. Eur Heart J. 2022 Nov 1;43(41):4362-4373. doi: 10.1093/eurheartj/ehac401. Eur Heart J. 2022. PMID: 35900838 Free PMC article. Clinical Trial.
At the end of treatment, the median (interquartile range) duration of follow-up was 27 (13-43) weeks, the adjusted mean change in potassium was +0.03 mmol/l in the patiromer group and +0.13 mmol/l in the placebo group [difference in the adjusted mean change between pati …
At the end of treatment, the median (interquartile range) duration of follow-up was 27 (13-43) weeks, the adjusted mean change in potassium …
A randomized study to compare oral potassium binders in the treatment of acute hyperkalemia.
Cañas AE, Troutt HR, Jiang L, Tonthat S, Darwish O, Ferrey A, Lotfipour S, Kalantar-Zadeh K, Hanna R, Lau WL. Cañas AE, et al. BMC Nephrol. 2023 Apr 5;24(1):89. doi: 10.1186/s12882-023-03145-x. BMC Nephrol. 2023. PMID: 37016309 Free PMC article. Clinical Trial.
METHODS: Emergency room and hospitalized patients with a blood potassium level 5.5 mEq/L are randomized to one of four study groups: potassium binder drug (sodium polystyrene sulfonate, patiromer, or sodium zirconium cyclosilicate) or nonspecific laxative (polyethylene gly …
METHODS: Emergency room and hospitalized patients with a blood potassium level 5.5 mEq/L are randomized to one of four study groups: potassi …
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.
Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, Ma J, White WB, Williams B. Agarwal R, et al. Lancet. 2019 Oct 26;394(10208):1540-1550. doi: 10.1016/S0140-6736(19)32135-X. Epub 2019 Sep 15. Lancet. 2019. PMID: 31533906 Clinical Trial.
FINDINGS: Between Feb 13, 2017, and Aug 20, 2018, we screened 574 patients. 295 (51%) of 574 patients met all inclusion criteria and were randomly assigned to spironolactone in addition to double-blind treatment with either placebo (n=148) or patiromer (n=147). At week 12, …
FINDINGS: Between Feb 13, 2017, and Aug 20, 2018, we screened 574 patients. 295 (51%) of 574 patients met all inclusion criteria and were ra …
Patiromer and Spironolactone in Resistant Hypertension and Advanced CKD: Analysis of the Randomized AMBER Trial.
Agarwal R, Rossignol P, Budden J, Mayo MR, Arthur S, Williams B, White WB. Agarwal R, et al. Kidney360. 2021 Jan 15;2(3):425-434. doi: 10.34067/KID.0006782020. eCollection 2021 Mar 25. Kidney360. 2021. PMID: 35369022 Free PMC article. Clinical Trial.
In this report, we compare the safety and efficacy of patiromer in advanced CKD as a prespecified analysis. RESULTS: Of the 295 patients randomized, 66 fell into the eGFR 25 to <30 subgroup. In this subgroup, persistent use of spironolactone was seen in 19 of 34 (56%) i …
In this report, we compare the safety and efficacy of patiromer in advanced CKD as a prespecified analysis. RESULTS: Of the 295 patie …
Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers.
Lesko LJ, Offman E, Brew CT, Garza D, Benton W, Mayo MR, Romero A, Du Mond C, Weir MR. Lesko LJ, et al. J Cardiovasc Pharmacol Ther. 2017 Sep;22(5):434-446. doi: 10.1177/1074248417691135. Epub 2017 Feb 13. J Cardiovasc Pharmacol Ther. 2017. PMID: 28585859 Free PMC article. Clinical Trial.
METHODS: Twelve randomized, open-label, 3-period, 3-sequence crossover studies were conducted in healthy volunteers to evaluate the effect of patiromer (perpetrator drug) on absorption and single-dose pharmacokinetics (PK) of drugs (victims) that might be commonly used wit …
METHODS: Twelve randomized, open-label, 3-period, 3-sequence crossover studies were conducted in healthy volunteers to evaluate the effect o …
Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors.
Kloner RA, Gross C, Yuan J, Conrad A, Pergola PE. Kloner RA, et al. J Cardiovasc Pharmacol Ther. 2018 Nov;23(6):524-531. doi: 10.1177/1074248418788334. Epub 2018 Aug 14. J Cardiovasc Pharmacol Ther. 2018. PMID: 30103622 Free PMC article. Clinical Trial.
We conducted post hoc analyses to provide the first report of patiromer in patients not taking RAASi. METHODS: Hyperkalemic patients received patiromer, 8.4 g/d to start, adjusted to achieve and maintain serum potassium of 3.8 to 5.0 mEq/L. ...Five patients (2 takin …
We conducted post hoc analyses to provide the first report of patiromer in patients not taking RAASi. METHODS: Hyperkalemic patients …
Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis.
Bushinsky DA, Rossignol P, Spiegel DM, Benton WW, Yuan J, Block GA, Wilcox CS, Agarwal R. Bushinsky DA, et al. Am J Nephrol. 2016;44(5):404-410. doi: 10.1159/000451067. Epub 2016 Oct 27. Am J Nephrol. 2016. PMID: 27784004 Free article. Clinical Trial.
On patiromer, P decreased from 7.0 0.5 to 6.2 0.5 mg/dl (p = 0.04). While on patiromer, fecal P numerically increased by 112 72 mg/day (17%; p = 0.1792; range -148 to 344 mg/day). No patient discontinued patiromer because of adverse events (AEs); none had ser …
On patiromer, P decreased from 7.0 0.5 to 6.2 0.5 mg/dl (p = 0.04). While on patiromer, fecal P numerically increased by 112 7 …
Effect of Patiromer on Urinary Ion Excretion in Healthy Adults.
Bushinsky DA, Spiegel DM, Gross C, Benton WW, Fogli J, Hill Gallant KM, Du Mond C, Block GA, Weir MR, Pitt B. Bushinsky DA, et al. Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1769-1776. doi: 10.2215/CJN.01170216. Epub 2016 Sep 27. Clin J Am Soc Nephrol. 2016. PMID: 27679518 Free PMC article. Clinical Trial.
BACKGROUND AND OBJECTIVES: Patiromer is a nonabsorbed potassium-binding polymer that uses calcium as the counterexchange ion. The calcium released with potassium binding has the potential to be absorbed or bind phosphate. Because binding is not specific for potassium, p …
BACKGROUND AND OBJECTIVES: Patiromer is a nonabsorbed potassium-binding polymer that uses calcium as the counterexchange ion. The cal …
Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
Butler J, Anker SD, Siddiqi TJ, Coats AJS, Dorigotti F, Filippatos G, Friede T, Göhring UM, Kosiborod MN, Lund LH, Metra M, Moreno Quinn C, Piña IL, Pinto FJ, Rossignol P, Szecsödy P, Van Der Meer P, Weir M, Pitt B. Butler J, et al. Eur J Heart Fail. 2022 Jan;24(1):230-238. doi: 10.1002/ejhf.2386. Epub 2021 Dec 9. Eur J Heart Fail. 2022. PMID: 34800079 Free PMC article. Clinical Trial.
Patients meeting the screening criteria will enter a single-blinded run-in phase where they will be started or continued on a mineralocorticoid receptor antagonist (MRA) titrated to 50 mg/day and other RAASi therapy to 50% target dose, and patiromer. Patiromer will …
Patients meeting the screening criteria will enter a single-blinded run-in phase where they will be started or continued on a mineralocortic …
Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA; AMETHYST-DN Investigators. Bakris GL, et al. JAMA. 2015 Jul 14;314(2):151-61. doi: 10.1001/jama.2015.7446. JAMA. 2015. PMID: 26172895 Clinical Trial.
OBJECTIVES: To select starting doses for a phase 3 study and to evaluate the long-term safety and efficacy of a potassium-binding polymer, patiromer, in outpatients with hyperkalemia. DESIGN, SETTING, AND PARTICIPANTS: Phase 2, multicenter, open-label, dose-ranging, random …
OBJECTIVES: To select starting doses for a phase 3 study and to evaluate the long-term safety and efficacy of a potassium-binding polymer, …
24 results